VANCOUVER, British Columbia — November 10, 2025 — Leads & Copy — Rakovina Therapeutics Inc., a biopharmaceutical company utilizing AI-enabled drug discovery to advance cancer therapies, announced new data will be presented in two posters at the Society for Neuro-Oncology (SNO) Annual Meeting in Honolulu, Hawaii, November 19–23, 2025.
The presentations will highlight Rakovina’s AI-driven programs focused on discovering and developing next-generation DNA-damage response (DDR) inhibitors engineered for central nervous system (CNS) penetration. This supports the development of potential new treatment options for primary and metastatic brain cancers.
The first poster presentation will detail the discovery and development of a novel CNS-penetrating ATR inhibitor, in a session titled “Poster Session – DNA Repair (DNAR-05)” scheduled for November 21, 2025, from 11:30 a.m. to 12:45 p.m. (HST). The second poster will present the progress from the Company’s kt-2000AI PARP inhibitor program and the discovery and development of novel CNS-penetrating PARP1-selective inhibitors, in a session titled “Poster Session – DNA Repair (DNAR-06)” also scheduled for November 21, 2025, from 11:30 a.m. to 12:45 p.m. (HST).
The first poster presents results from Rakovina Therapeutics’ kt-5000AI ATR inhibitor program, developed in collaboration with Variational AI. The program leverages the ENKI™ generative AI platform to design and optimize CNS-penetrant ATR inhibitors with favorable pharmacologic properties for the potential treatment of brain cancers. The data highlight the discovery of potent, selective ATR inhibitors that demonstrate activity against treatment-resistant tumor phenotypes.
The second poster presents progress from the Company’s kt-2000AI PARP inhibitor program, developed using the Deep Docking™ AI-accelerated drug discovery platform. The program applies ultra-large-scale virtual screening to evaluate billions of compounds in silico, rapidly identifying and optimizing PARP1-selective, CNS-penetrant inhibitors with desirable pharmacologic properties. The data illustrate how this approach enables deep exploration of chemical space and efficient discovery of next-generation candidates designed to address the limitations of first-generation PARP inhibitors.
Prof. Mads Daugaard, President and Chief Scientific Officer of Rakovina Therapeutics, stated that the Society for Neuro-Oncology Annual Meeting is a premier global forum for advances in brain cancer research, and the company is proud to share its latest data at this year’s conference. Daugaard noted that Rakovina’s participation reflects its ongoing efforts to develop first-in-class DNA-damage response inhibitors designed to reach the brain and that by combining AI-accelerated medicinal chemistry with the world-class infrastructure at the University of British Columbia’s Vancouver Prostate Centre, the company is advancing next-generation therapies targeting ATR and PARP1 pathways aimed at improving outcomes for patients with aggressive and treatment-resistant brain cancers.
The Society for Neuro-Oncology (SNO) Annual Meeting, held in partnership with the World Federation of Neuro-Oncology Societies (WFNOS), is dedicated to advancing the science and treatment of brain cancers. The 2025 meeting will unite leading researchers, clinicians, and industry innovators to showcase discoveries and emerging therapeutic strategies in neuro-oncology. It provides an opportunity for visibility and collaboration across the global brain cancer community. More information can be found at https://www.soc-neuro-onc.org/SNO2025/SNO2025/Home.aspx
Rakovina Therapeutics Inc. is focused on the development of innovative cancer treatments. The company utilizes unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking™ and Enki™ platforms to review and optimize drug candidates. Rakovina Therapeutics has a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing drug candidates into human clinical trials in collaboration with pharmaceutical partners.
For Further Information Contact:
Michelle Seltenrich, BSc MBA
Director, Corporate Development
IR@rakovinatherapeutics.com
778-773-5432
Source: Source: Rakovina Therapeutics Inc.
